Wedbush Reiterates Outperform on Rocket Pharmaceuticals, Maintains $15 Price Target
Wedbush analyst Yun Zhong reiterates Rocket Pharmaceuticals (NASDAQ:RCKT) with a Outperform and maintains $15 price target.
Stocks · News reference
8-K filing — ROCKET PHARMACEUTICALS, INC. (RCKT)
Filed: 2026-10-06 AccNo: 0001140361-26-038818 Size: 10 MB Item 1.01: Entry into a Material Definitive Agreement Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant Item 3.02: Unregistered Sales of Equity Securities Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- edgar
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Rocket Pharmaceuticals Announces Up To $150M Credit Facility With Hercules Capital, $35M Received At Closing; Expects Cash Runway Into Q3 2028
This JB Hunt Transport Analyst Turns Bullish; Here Are Top 4 Upgrades For Thursday
Analysts upgraded SUNB, HAWK, and more, revising ratings and price targets.